We investigated the effectiveness of additional markers (i.e., CD200, CD81, CD28, and CD117) at pre-MM stage (MGUS/SMM), at initial diagnosis of MM (ID), during disease progression (PD), under anti-MM treatment, and whether they could provide a similar or increased reliability in identification of aPC compared to kappa/lambda. Here, CD81 is linked to Miyoshi myopathy.